On Stockhead today, dementia is the new heart disease – these ASX stocks are in the fight, cleaning up on ex-div CBA, and is the gig economy growing again?

But first, the day ahead.

 

TRADING HALTS

The following stocks went into trading halts Friday and are expected out in the coming days:

Metals Australia (ASX:MLS) – Announcement about graphite purification test work on its Lac Rainy Graphite Project in Canada

Haranga Resources (ASX:HAR) – Drill results from the Saraya uranium project

MLG Oz (ASX:MLG) – Company set to dispose of its “two high capacity crushing plants”, so if you’ve ever wanted to win “Largest Pumpkin” and squash several people at your local agricultural show, here’s your chance.

Bravura Solutions (ASX:BVS) – Announcement in relation to its business performance and guidance

Mt Monger Resources (ASX:MTM) – Capital raising

Top Shelf International Holdings (ASX:TSI) – Capital raising

Sheffield Resources (ASX:SFX) – Material investment and equity raising

Kaddy (ASX:KDY) – Capital raising

Ten Sixty Four (ASX:X64) – Operational update on the Co-O gold mine

Dateline Resources (ASX:DTR) – Capital raising

 

COMMODITY/FOREX/CRYPTO MARKET PRICES

Gold: $US1,810.9 (-0.64%)

Silver: $US20.76 (-2.50%)

Nickel (3mth): $US25,387/t (-3.95%)

Copper (3mth): $US8904.00/t (-2.28%)

Oil (WTI): $US76.32 (+1.23%)

Oil (Brent): $US83.34 (+1.37%)

Iron 62pc Fe: $US131.5/t (-1.13%)

AUD/USD: 0.6725 (-1.20%)

Bitcoin: $US23,236 (+0.52%)

 

WHAT GOT YOU TALKING OVER THE WEEKEND?

Bannerman Energy (ASX:BMN) CEO Brandon Munro says 2023 has marked a positive shift in uranium sentiment, driven by this accumulation of bullish news since 2019.

This could be the year things finally explode.

 

Keep up to date with Stockhead coverage or you’ll miss gold like that EVERY DAY. Follow our Twitter page.

For all you crypto lovers Stockhead’s Coinhead Facebook group is the place to share your views, insights, tips and ideas.

Also, be sure to check in preopen each day for ‘Market highlights and 5 ASX small caps to watch’, and 10.30am for our daily ‘10 at 10’ column — a live summary of winners & losers at the opening bell.

 

LAST WEEK’S ASX SMALL CAP LEADERS

Here are last week’s best performing ASX small cap stocks:

Swipe or scroll to reveal full table. Click headings to sort:

Wordpress Table Plugin

Mining services business Metarock (ASX:MYE)  settled its beef over the the Gregory Crinum contract with Japan’s Sojitz Corporation.

It will pocket $11.1 million plus sell off a bunch of equipment it brought in for the project but is now surplus to requirements.

Mt Monger Resources (ASX:MTM) will buy the Pomme hard rock rare earths project in Quebec, Canada, from TSX listed explorer Geomega Resources for ~$1m in cash and shares.

The company says it has similar geology to Geomega’s advanced 266Mt Montviel carbonatite REE-Nb deposit, just 7km away.

Zinc miner New Century Resources (ASX:NZS)  received a takeover offer from disgruntled major shareholder (19.9%) Sibanye-Stillwater at $1.10 per share – a 42.9% premium on the last traded price.

Shareholders ignored the NCZ board who recommended they take no action in response to the bid, and jumped at the opportunity to divest their holdings.

A change in substantial holding notice posted to the ASX Friday said the South African-American platinum and gold giant had acquired a further 41.5m shares since making its announcement earlier in the week, taking its voting power past 50% to 51.41%.

 

LAST WEEK’S ASX SMALL CAP LAGGARDS

Here are last week’s worst performing ASX small cap stocks:

Swipe or scroll to reveal full table. Click headings to sort:

Wordpress Table Plugin

US aluminium giant Alcoa pulled out of a deal to develop FYI Resources’ (ASX:FYI) high purity alumina project in Perth, WA.

The now scrapped agreement would’ve seen Alcoa acquire 65% of the project by spending $US243m on project development.

The project now reverts to FYI, who “will develop an alternative plan and schedule” for development.

Biotech Cogstate (ASX:CGS) released FY23 guidance ahead of its half year report and it doesn’t make for good reading.

Revenue delays are expected to continue to impact earnings in 2H23, it says, with some revenue from those impacted trials now expected to be recognised in FY24.

It expects to report breakeven profit before tax for 1H23.

It then was forced by the ASX to tell investors that a now abandoned takeover deal had been in the works between late December and January, a period which saw the stock gain +20% on no news.